{
    "root": "3465ea08-4468-da4e-e063-6294a90a11b5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Paroxetine",
    "value": "20250505",
    "ingredients": [
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_181906"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "PAROXETINE HYDROCHLORIDE",
            "code": "X2ELS050D8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7944"
        }
    ],
    "indications": {
        "text": "paroxetine tablets indicated adults treatment : major depressive disorder ( mdd ) obsessive compulsive disorder ( ocd ) panic disorder ( pd ) social anxiety disorder ( sad ) generalized anxiety disorder ( gad ) posttraumatic stress disorder ( ptsd )",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "obsessive compulsive disorder (DOID:10933)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10933"
            },
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended starting maximum daily mdd , ocd , pd , ptsd : ( 2.2 ) indication starting daily dose maximum daily dose mdd 20 mg 50 mg ocd 20 mg 60 mg pd 10 mg 60 mg ptsd 20 mg 50 mg recommended starting sad gad 20 mg daily . ( 2.3 ) elderly patients , patients severe renal impairment severe hepatic impairment : starting 10 mg daily . maximum 40 mg daily . ( 2.4 ) discontinuing paroxetine tablets , reduce gradually . ( 2.6 , 5.7 )",
        "doid_entities": [
            {
                "text": "ocd (DOID:84)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_84"
            },
            {
                "text": "ptsd (DOID:2055)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2055"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "paroxetine tablets , usp available containing paroxetine hydrochloride , usp ( hemihydrate ) equivalent 10 mg paroxetine . 10 mg tablets blue , film-coated , modified capsule-shaped , scored tablets debossed one side tablet n left score 1 right score side . available follows : ndc 72789-037-45 bottles 45 tablets ndc 72789-037-90 bottles 90 tablets store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] dispense tight , light-resistant container defined usp using child-resistant closure . pharmacist : dispense medication guide prescription .",
    "adverseReactions": "paroxetine tablets contraindicated patients : taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7 ) ] . taking thioridazine risk qt prolongation [ ( 5.3 ) , ( 7 ) ] . taking pimozide risk qt prolongation [ ( 5.3 ) , ( 7 ) ] . known hypersensitivity ( e.g . , anaphylaxis , angioedema , stevens-johnson syndrome ) paroxetine inactive ingredients paroxetine tablets [ ( 6.1 ) , ( 6.2 ) ] .",
    "indications_original": "Paroxetine tablets are indicated in adults for the treatment of:\n                  \n                     Major depressive disorder (MDD)\n                     Obsessive compulsive disorder (OCD)\n                     Panic disorder (PD)\n                     Social anxiety disorder (SAD)\n                     Generalized anxiety disorder (GAD)\n                     Posttraumatic stress disorder (PTSD)",
    "contraindications_original": "Recommended starting and maximum daily dosage for MDD, OCD, PD, and PTSD: ( 2.2 ) Indication Starting Daily Dose Maximum Daily Dose MDD 20 mg 50 mg OCD 20 mg 60 mg PD 10 mg 60 mg PTSD 20 mg 50 mg Recommended starting dosage for SAD and GAD is 20 mg daily. ( 2.3 ) Elderly patients, patients with severe renal impairment or severe hepatic impairment: Starting dosage is 10 mg daily. Maximum dosage is 40 mg daily. ( 2.4 ) When discontinuing paroxetine tablets, reduce dosage gradually. ( 2.6 , 5.7 )",
    "warningsAndPrecautions_original": "Paroxetine Tablets, USP are available containing paroxetine hydrochloride, USP (hemihydrate) equivalent to 10 mg of paroxetine.\n                  The 10 mg tablets are blue, film-coated, modified capsule-shaped, scored tablets debossed with \n  M on one side of the tablet and \n  N to the left of the score and \n  1 to the right of the score on the other side. They are available as follows:\n \n                  NDC 72789-037-45\n  \nbottles of 45 tablets\n \n                  NDC 72789-037-90\n  \nbottles of 90 tablets\n \n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  \n                     PHARMACIST: Dispense a Medication Guide with each prescription.",
    "adverseReactions_original": "Paroxetine tablets are contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [see\n   \n    Warnings and Precautions (5.2),\n   \n    Drug Interactions (7)]\n  \n   .\n \n  \n                     Taking thioridazine because of risk of QT prolongation\n  \n   [see\n   \n    Warnings and Precautions (5.3),\n   \n    Drug Interactions (7)]\n  \n   .\n \n  \n                     Taking pimozide because of risk of QT prolongation\n  \n   [see\n   \n    Warnings and Precautions (5.3),\n   \n    Drug Interactions (7)]\n  \n   .\n \n  \n                     With known hypersensitivity (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome) to paroxetine or any of the inactive ingredients in paroxetine tablets\n  \n   [see\n   \n    Adverse Reactions (6.1),\n   \n    (6.2)]\n  \n   .",
    "drug": [
        {
            "name": "Paroxetine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7936"
        }
    ]
}